Radiopharmaceutical Switch Maintenance for Relapsed Ovarian Carcinoma

Switch maintenance, or using alternative therapeutic agents that were not administered during a prior course of cancer treatment, has emerged as an active clinical research and regulatory agency-approvable path in the National Cancer Institute (NCI) Cancer Therapy Evaluation Program (CTEP) drug-deve...

Descripción completa

Detalles Bibliográficos
Autores principales: Kunos, Charles A., Capala, Jacek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Opinion
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7600139/
https://www.ncbi.nlm.nih.gov/pubmed/33008086
http://dx.doi.org/10.3390/ph13100287

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7600139/
https://www.ncbi.nlm.nih.gov/pubmed/33008086
http://dx.doi.org/10.3390/ph13100287

Ejemplares similares